Clinical Trials on Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma

Total 807 results

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (IMAGINE)

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (AMBASSADOR)

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Ureter Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Localized Renal Pelvis and Ureter Urothelial Carcinoma | Stage II Bladder... and other conditions

United States, Guam
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III... and other conditions

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma

United States
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Hydronephrosis | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Renal Pelvis Cancer AJCC v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Renal Pelvis Cancer AJCC v7 | Stage IV... and other conditions

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
UroGen Pharma Ltd.

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (uTRACT)

Carcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal Pelvis

United States
University of California, Davis
Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Recurrent Bladder Carcinoma | Stage III Urethral Cancer | Stage IV Urethral Cancer | Urethral Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter | Stage III Bladder Urothelial Carcinoma | Recurrent Urothelial Carcinoma of... and other conditions

United States
UroGen Pharma Ltd.
Tanner Pharma Group

Available

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent
University of British Columbia

Recruiting

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

Transitional Cell Cancer of the Renal Pelvis and Ureter | Urothelial Carcinoma of the Renal Pelvis and Ureter

Canada
M.D. Anderson Cancer Center

Active, not recruiting

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Malignant Solid Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Unresectable Melanoma | Clinical Stage III Cutaneous... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
Dr Anders Ullén
Bayer; Pierre Fabre Laboratories; Nordic Urothelial Cancer Oncology Group

Completed

Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR)

Bladder Cancer | Urothelial Carcinoma | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer

Denmark, Sweden
University of Alabama at Birmingham
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Completed

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)

United States
Dr Anders Ullén

Completed

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function (VINGEM)

Bladder Cancer | Urothelial Carcinoma | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer

Denmark, Sweden
Dana-Farber Cancer Institute
Gilead Sciences

Active, not recruiting

Sacituzumab Govitecan Plus EV in Metastatic UC

Bladder Cancer | Urothelial Cancer | Metastatic Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma | Recurrent Urethral Urothelial Carcinoma | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage 0a Bladder Cancer... and other conditions

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
Principia Biopharma, a Sanofi Company

Terminated

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

Solid Tumors | Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter

Spain, United States
McMaster University

Not yet recruiting

Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter
University of Washington
National Cancer Institute (NCI)

Recruiting

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Bladder Carcinoma | Recurrent Prostate Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Localized... and other conditions

United States
University of Texas Southwestern Medical Center

Recruiting

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Malignant Solid Neoplasm | Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage... and other conditions

United States
Mirati Therapeutics Inc.

Terminated

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma Bladder | Urothelial Carcinoma | Urothelial Carcinoma Ureter | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Urethra

United States
Mamta Parikh
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial Carcinoma

United States
Xuesong Li

Recruiting

Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Urothelial Carcinoma Ureter | Locally Advanced

China
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Localized Transitional Cell Cancer of the...

United States
University of Utah
National Cancer Institute (NCI)

Recruiting

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE)

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid Variant

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
Fox Chase Cancer Center

Recruiting

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Carcinoma, Transitional Cell | Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

Bladder Cancer | Ureter Cancer | Renal Pelvis Cancer

United States
Emory University
National Cancer Institute (NCI); Exelixis

Recruiting

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; University of Chicago

Recruiting

A Genotype-Phenotype Urothelial Cancer Registry

Bladder Cancer | Urothelial Cancer | Ureter Cancer | Renal Pelvis Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Stage II Bladder Cancer AJCC v8 | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall | Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma

United States
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma

China
Spanish Oncology Genito-Urinary Group
Roche Pharma AG

Completed

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA)

Locally Advanced or Metastatic Urothelial Carcinoma

Spain
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditions

United States
National Cancer Institute (NCI)

Completed

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter

United States

Clinical Trials on Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations